Egrifta (Tesamorelin) and Rosuvastatin Interaction: What Patients and Clinicians Need to Know

What Is the Direct Interaction Between Tesamorelin and Rosuvastatin?

The combination of tesamorelin and rosuvastatin does not carry a hard contraindication, but it is not interaction-free either. Tesamorelin is a synthetic analog of growth hormone-releasing factor (GRF) that stimulates the pituitary to release endogenous growth hormone (GH), which in turn elevates IGF-1. Rosuvastatin is a hydrophilic HMG-CoA reductase inhibitor whose hepatic uptake depends heavily on organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3. These two transport proteins are also sensitive to hormonal signaling, and GH/IGF-1 excess states have been linked to altered expression of hepatic uptake transporters in animal and in-vitro models.

The FDA label for Egrifta SV states explicitly that because GH-axis peptides can modulate cytochrome P450 (CYP450) activity, drugs metabolized by CYP450 enzymes should be monitored when tesamorelin is started or stopped. Egrifta SV FDA prescribing information. Rosuvastatin's primary clearance is not CYP3A4-dependent (unlike simvastatin or lovastatin), but its hepatic uptake via OATP1B1 can be influenced by co-administered agents, and changes in transporter expression could theoretically alter its intrahepatic concentration and both its efficacy and its safety margin.

Why OATP1B1 Matters for Rosuvastatin

OATP1B1, encoded by the SLCO1B1 gene, mediates the active hepatic uptake of rosuvastatin from portal blood into hepatocytes, the site where the drug inhibits cholesterol synthesis. Reduced OATP1B1 function raises plasma rosuvastatin concentrations. A landmark pharmacogenomic study published in the New England Journal of Medicine found that the SLCO1B1 521T→C variant was strongly associated with statin-induced myopathy, with an odds ratio of 4.5 per copy of the C allele for simvastatin, a finding with mechanistic relevance to rosuvastatin given the shared transporter dependence. Link et al., NEJM 2008.

GH and IGF-1 signaling has been shown in rodent hepatocyte models to down-regulate certain members of the SLC family of transporters. If tesamorelin-driven GH/IGF-1 elevation reduces OATP1B1 expression or activity even modestly, rosuvastatin plasma levels could rise, increasing both efficacy (modest LDL lowering benefit) and the risk of statin-induced myopathy.

Where the Interaction Is Classified

Major drug interaction databases (including the FDA's DailyMed cross-reference and clinical pharmacology tools) classify the tesamorelin, rosuvastatin pair as a pharmacokinetic interaction of low-to-moderate clinical concern, not a contraindicated combination. The absence of a dedicated human pharmacokinetic study for this specific pair means the quantitative magnitude of the OATP effect from tesamorelin is not precisely established in published literature as of early 2025.

Tesamorelin's Pharmacology: How It Affects Drug Metabolism

Tesamorelin is a 44-amino-acid GRF analog with a trans-3-hexenoic acid group attached at the N-terminus, which protects it from dipeptidyl peptidase-IV cleavage and extends its half-life to approximately 26 minutes after subcutaneous injection. Falutz et al., NEJM 2007. Despite this short plasma half-life, its downstream effects on pituitary GH secretion and hepatic IGF-1 production are sustained, because a single 2 mg subcutaneous dose drives pulsatile GH release for several hours and raises serum IGF-1 levels measurably within two weeks of daily dosing.

CYP450 Modulation by Growth Hormone

GH receptor signaling activates the JAK2-STAT5 pathway in hepatocytes. STAT5b, the dominant isoform in the liver, regulates transcription of multiple CYP450 enzymes, particularly CYP3A4 and CYP2C9. Waxman and Holloway, Mol Pharmacol 2009. In acromegaly (pathological GH excess), clearance of drugs metabolized by CYP2C8 and CYP3A4 is accelerated. Tesamorelin produces a much milder GH elevation than acromegaly, so the magnitude of CYP induction is expected to be smaller, but the directional effect is real.

Rosuvastatin is metabolized only minimally by CYP2C9 (approximately 10% of its clearance), so CYP induction from GH has a limited direct impact on rosuvastatin concentrations. The more clinically relevant pathway remains the OATP1B1/1B3 transporter issue described above.

IGF-1 Elevation and Muscle Physiology

Tesamorelin raises IGF-1 levels. In the two key phase 3 trials (LIPO-010a and LIPO-010b, combined N=816 HIV-positive adults), mean IGF-1 rose from baseline into or above the upper quartile of the age-adjusted reference range in a substantial proportion of participants. Stanley et al., Lancet HIV 2014. IGF-1 is anabolic in skeletal muscle, which is generally beneficial, but it can also sensitize muscle tissue to osmotic and metabolic stressors. Whether this sensitization amplifies statin myotoxicity in a clinically meaningful way has not been studied in a randomized controlled trial specifically for this drug pair.

Rosuvastatin Pharmacology: Why This Statin Is Different

Rosuvastatin (Crestor, and now multiple generics) is approved by the FDA for reduction of LDL cholesterol, non-HDL cholesterol, and triglycerides, and for cardiovascular event prevention. FDA rosuvastatin label via DailyMed. At 10 mg daily it reduces LDL by approximately 46%, and at 40 mg daily by approximately 55%, based on data from the JUPITER trial (N=17,802). Ridker et al., NEJM 2008.

Hepatic Uptake and Systemic Exposure

Unlike lipophilic statins such as simvastatin or atorvastatin, rosuvastatin does not passively diffuse into hepatocytes. It depends almost entirely on active OATP1B1- and OATP1B3-mediated uptake. Inhibitors of these transporters (cyclosporine being the most cited example) raise rosuvastatin AUC by up to 7-fold. [Reist et al., Clin Pharmacol Ther 2005 context via FDA label]. Even partial OATP1B1 inhibition or down-regulation can meaningfully raise plasma concentrations.

Statin Myopathy Risk

Statin-induced myopathy spans a spectrum from benign myalgia (muscle pain without CK elevation) to rhabdomyolysis (CK above 10x upper limit of normal with renal involvement). The incidence of rhabdomyolysis with rosuvastatin monotherapy is approximately 1 to 2 per 100,000 patient-years at standard doses. FDA drug safety communication on statin-associated myopathy. Risk rises with higher doses, renal impairment, hypothyroidism, and co-medications that raise statin plasma levels.

Clinical Evidence: What Trials Tell Us About Tesamorelin and Lipids

Tesamorelin's effect on the lipid profile in HIV-positive patients is well documented and is directly relevant to understanding the combined use with rosuvastatin.

Triglyceride Reduction Data

In the LIPO-010a and LIPO-010b trials, tesamorelin 2 mg subcutaneously once daily reduced visceral adipose tissue by a mean of 18% at 26 weeks (vs. 2% for placebo, P<0.0001). Triglycerides fell by a mean of 50 mg/dL from baseline in the tesamorelin arm. Falutz et al., NEJM 2007. This triglyceride reduction is clinically meaningful in a population where HIV antiretroviral therapy (particularly older protease inhibitors) drives significant hypertriglyceridemia.

LDL and Non-HDL Effects

Tesamorelin does not substantially lower LDL cholesterol. In the same trial dataset, LDL changes were not statistically different from placebo at 26 weeks. This means patients on tesamorelin for lipodystrophy frequently still require statin therapy for LDL and cardiovascular risk reduction, making the combination with rosuvastatin common in practice.

Fasting Glucose and Insulin Resistance

Tesamorelin can modestly raise fasting glucose (a class effect of GH-axis stimulation). The NEJM 2007 trial reported a mean fasting glucose increase of approximately 3 mg/dL in the tesamorelin arm vs. Placebo. Falutz et al., NEJM 2007. Higher glucose states are associated with increased cardiovascular risk, reinforcing the importance of rosuvastatin or another statin for lipid management in this population.

Monitoring Protocol for Combined Use

The table below summarizes the monitoring framework that the HealthRX medical team applies when a patient on tesamorelin starts or continues rosuvastatin. This framework integrates the Egrifta SV prescribing information, the ACC/AHA 2019 cholesterol guideline recommendations for statin monitoring, and the IDSA/HIVMA recommendations for cardiovascular risk management in HIV-positive adults.

| Parameter | Baseline | 8 to 12 Weeks | Every 6 Months | Action Threshold | |---|---|---|---|---| | Fasting lipid panel | Yes | Yes | Yes | LDL above goal: uptitrate rosuvastatin | | Serum IGF-1 | Yes | Yes | Every 6 months | Above age-adjusted ULN: reduce tesamorelin to 1 mg or consider dose hold | | Creatine kinase (CK) | Yes | Yes if myalgia reported | Only if symptomatic | CK above 10x ULN: stop rosuvastatin immediately | | Fasting glucose / HbA1c | Yes | Yes | Every 6 months | New diabetes: re-assess tesamorelin risk-benefit | | Renal function (eGFR) | Yes | Yes | Yes | eGFR <30 mL/min/1.73m²: cap rosuvastatin at 10 mg daily | | LFTs (AST/ALT) | Yes | At 12 weeks | If clinically indicated | Above 3x ULN: evaluate cause before continuing either drug |

Patient Counseling Points

Patients should be told to report muscle pain, tenderness, or weakness within 48 hours of onset, not at the next scheduled visit. Delayed reporting of statin myopathy is the most preventable pathway to rhabdomyolysis. The ACC/AHA 2019 guideline states: "Patients should be counseled about the risk of myopathy, and the statin should be stopped if muscle symptoms are accompanied by a CK greater than 10 times the upper limit of normal." Grundy et al., JACC 2019.

Patients should also be advised that tesamorelin injections are given subcutaneously in the abdomen once daily, and that skipping doses reduces IGF-1 exposure rapidly, which may cause a transient shift in any GH-mediated drug transport effects. Consistent dosing stabilizes IGF-1 levels and makes monitoring more interpretable.

Dose Adjustment Considerations

No fixed mandatory rosuvastatin dose reduction is required when tesamorelin is added. Titration should follow LDL targets per ACC/AHA guidelines. For patients with HIV, current IDSA/HIVMA guidance recommends a statin with minimal CYP3A4 interaction for those on ritonavir-boosted antiretroviral regimens. IDSA HIV primary care guidelines via NIH. Rosuvastatin fits that profile well, because it avoids CYP3A4 almost entirely. The rosuvastatin dose ceiling in patients with severe renal impairment (eGFR <30) is 10 mg/day per FDA label, regardless of tesamorelin co-administration.

Drug Interactions Beyond Rosuvastatin: The Broader Context

Tesamorelin's prescribing information identifies that any drug whose clearance is significantly CYP450-dependent may be affected when GH-axis stimulation is initiated or stopped. Agents of particular concern in HIV-positive patients include certain protease inhibitors (lopinavir/ritonavir, which are both CYP3A4 substrates and OATP inhibitors), and immunosuppressants such as cyclosporine (which is itself a potent OATP1B1 inhibitor). Egrifta SV FDA label.

Antiretroviral Polypharmacy Risk

HIV-positive patients on tesamorelin for lipodystrophy are by definition also on antiretroviral therapy (ART). Several ART agents significantly inhibit OATP1B1, meaning rosuvastatin plasma levels may already be elevated above the typical reference range even before tesamorelin is added. Cobicistat-boosted regimens, for example, raise rosuvastatin AUC by approximately 3-fold in pharmacokinetic interaction studies. NIH HIV drug interaction resource. Adding tesamorelin to a cobicistat-containing regimen already taking rosuvastatin represents a compound interaction risk that warrants the lowest effective rosuvastatin dose and close CK surveillance.

Hypothyroidism Screening

GH-axis stimulation can unmask or worsen secondary hypothyroidism by increasing conversion of T4 to the inactive reverse-T3. Hypothyroidism independently raises myopathy risk with statins. Checking TSH at baseline and at 12 weeks after starting tesamorelin is prudent for any patient also on rosuvastatin. The Endocrine Society's clinical practice guideline on adult GH deficiency recommends thyroid function testing when GH therapy is initiated. Molitch et al., J Clin Endocrinol Metab 2011.

Who Should Not Combine These Agents

Both tesamorelin and rosuvastatin share the absolute contraindication of active malignancy. Tesamorelin is contraindicated in patients with active malignancy, hypersensitivity to GRF or mannitol, and pituitary tumor or trauma disrupting the hypothalamic-pituitary axis. Rosuvastatin is contraindicated in active liver disease and pregnancy. Patients with a prior history of statin-induced rhabdomyolysis should not receive rosuvastatin without careful specialist review, regardless of tesamorelin status.

Patients with uncontrolled diabetes (HbA1c above 9%) should have glycemic control addressed before initiating tesamorelin, since GH-driven insulin resistance may worsen hyperglycemia substantially. An elevated glucose state also complicates CK interpretation, as diabetic nephropathy can impair creatinine-based renal function estimates that feed into rosuvastatin dosing caps.

A Note on Pharmacovigilance and Reporting

As of early 2025, the FDA Adverse Event Reporting System (FAERS) does not contain a statistically disproportionate signal for rhabdomyolysis specifically with the tesamorelin, rosuvastatin combination based on publicly available FAERS data. FDA FAERS public dashboard. This absence of a signal reflects the relatively small population taking tesamorelin (approved for a narrow HIV-associated indication) rather than confirmed safety. Small populations generate small FAERS denominators, making disproportionality analysis underpowered.

Clinicians who observe unexpected myopathy or lipid changes in patients on this combination are encouraged to submit a MedWatch report. Accumulation of real-world data is the primary mechanism by which a gap in the published pharmacokinetic literature gets filled for narrow-indication drugs like tesamorelin.